167 related articles for article (PubMed ID: 36386101)
1. Efficacy, Safety and Quality of Life of Oxybutynin versus Aluminum Chloride Hexahydrate in Treating Primary Palmar Hyperhidrosis.
Attallah HS; El-Gilany AH; Youssef YEB; Abdelshaheed ME; Sharaf EFA
Indian J Dermatol; 2022; 67(3):222-227. PubMed ID: 36386101
[TBL] [Abstract][Full Text] [Related]
2. Topical Oxybutynin 3% Gel Versus Aluminum Chloride 15% Lotion in Treatment of Primary Focal Hyperhidrosis.
El-Agamy El-Samadony A; Hegab DS; El Maghraby GM; El-Maadawy IH
Dermatol Pract Concept; 2023 Jul; 13(3):. PubMed ID: 37557105
[TBL] [Abstract][Full Text] [Related]
3. Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial.
Saki N; Shakouri N; Rastaghi F; Hosseini SA; Alipour S; Ahramiyanpour N
J Cosmet Dermatol; 2023 Aug; 22(8):2268-2272. PubMed ID: 36999480
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study.
Campanati A; Gregoriou S; Consales V; Rizzetto G; Bobyr I; Diotallevi F; Martina E; Kontochristopoulos G; Platsidaki E; Offidani A
Dermatol Ther; 2020 Nov; 33(6):e14039. PubMed ID: 32691938
[TBL] [Abstract][Full Text] [Related]
5. Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis.
Wolosker N; Krutman M; Teivelis MP; Campbell TP; Kauffman P; de Campos JR; Puech-Leão P
Ann Vasc Surg; 2014 May; 28(4):970-6. PubMed ID: 24333527
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old.
Wolosker N; Schvartsman C; Krutman M; Campbell TP; Kauffman P; de Campos JR; Puech-Leão P
Pediatr Dermatol; 2014; 31(1):48-53. PubMed ID: 23627681
[TBL] [Abstract][Full Text] [Related]
7. A comparative evaluation of aluminum chloride hexahydrate gel iontophoresis versus tap water iontophoresis in people with primary palmar hyperhidrosis: A randomised clinical trial.
Majid Hosseini S; Ghandali E; Reza Moghimi H; Khademi-Kalantari K; Talebian Moghaddam S; Akbarzadeh Baghban A; Maryam Mortazavi S
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):52-58. PubMed ID: 37436009
[TBL] [Abstract][Full Text] [Related]
8. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Wolosker N; de Campos JR; Kauffman P; Puech-Leão P
J Vasc Surg; 2012 Jun; 55(6):1696-700. PubMed ID: 22341836
[TBL] [Abstract][Full Text] [Related]
9. An alternative to treat palmar hyperhidrosis: use of oxybutynin.
Wolosker N; de Campos JR; Kauffman P; Neves S; Yazbek G; Jatene FB; Puech-Leão P
Clin Auton Res; 2011 Dec; 21(6):389-93. PubMed ID: 21688168
[TBL] [Abstract][Full Text] [Related]
10. Real-life experience with oral oxybutynin long-term continuous therapy in severe hyperhidrosis and systematic review of the literature.
Briatico G; Pampena R; Fulgione E; Babino G; Giorgio CM; D'Ambra I; Caccavale S; Longo C; Argenziano G
Dermatol Ther; 2021 Mar; 34(2):e14832. PubMed ID: 33527699
[TBL] [Abstract][Full Text] [Related]
11. Oxybutynin in primary hyperhidrosis: A long-term real-life study.
Almeida ART; Ferrari F; Restrepo MVS; Rocha VB
Dermatol Ther; 2020 Nov; 33(6):e14344. PubMed ID: 32981151
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases.
Wolosker N; Kauffman P; de Campos JRM; Faustino CB; da Silva MFA; Teivelis MP; Puech-Leão P
Int J Dermatol; 2020 Jun; 59(6):709-715. PubMed ID: 32301117
[TBL] [Abstract][Full Text] [Related]
13. Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin.
Teivelis MP; Wolosker N; Krutman M; Kauffman P; Campos JR; Puech-Leão P
Clinics (Sao Paulo); 2014 Sep; 69(9):608-14. PubMed ID: 25318092
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects With Primary Focal Hyperhidrosis.
Pariser DM; Krishnaraja J; Tremblay TM; Rubison RM; Love TW; McGraw BF
J Drugs Dermatol; 2017 Feb; 16(2):127-132. PubMed ID: 28300854
[TBL] [Abstract][Full Text] [Related]
15. A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study.
Fujimoto T; Terahara T; Okawa K; Inakura H; Hirayama Y; Yokozeki H
J Am Acad Dermatol; 2023 Jul; 89(1):62-69. PubMed ID: 36990320
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Efficacy of Oxybutynin for Palmar and Plantar Hyperhidrosis in Children Younger than 14 Years.
Wolosker N; Teivelis MP; Krutman M; de Paula RP; Schvartsman C; Kauffman P; de Campos JR; Puech-Leão P
Pediatr Dermatol; 2015; 32(5):663-7. PubMed ID: 25490865
[TBL] [Abstract][Full Text] [Related]
17. [Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
Try C; Messikh R; Elkhyat A; Aubin F; Humbert RP
Rev Med Liege; 2012 Oct; 67(10):520-6. PubMed ID: 23167161
[TBL] [Abstract][Full Text] [Related]
18. The use of oxybutynin for treating axillary hyperhidrosis.
Wolosker N; de Campos JR; Kauffman P; Neves S; Munia MA; BiscegliJatene F; Puech-Leão P
Ann Vasc Surg; 2011 Nov; 25(8):1057-62. PubMed ID: 22023940
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of oxybutynin for treatment of hyperhidrosis in overweight and obese patients.
Wolosker N; Krutman M; Kauffman P; Paula RP; Campos JR; Puech-Leão P
Rev Assoc Med Bras (1992); 2013; 59(2):143-7. PubMed ID: 23582555
[TBL] [Abstract][Full Text] [Related]
20. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial.
Schollhammer M; Brenaut E; Menard-Andivot N; Pillette-Delarue M; Zagnoli A; Chassain-Le Lay M; Sassolas B; Jouan N; Le Ru Y; Abasq-Thomas C; Greco M; Penven K; Roguedas-Contios AM; Dupré-Goetghebeur D; Gouedard C; Misery L; Le Gal G
Br J Dermatol; 2015 Nov; 173(5):1163-8. PubMed ID: 26114588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
